Janez IlaÅ

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2453844/publications.pdf

Version: 2024-02-01

76	1,805	279701 23	315616 38
papers	citations	h-index	g-index

80	80	80	2200
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Design, Synthesis, inâ€...vitro and in silico Characterization of 2â€Quinoloneâ€Lâ€alanineâ€1,2,3â€triazoles as Antimicrobial Agents. ChemMedChem, 2022, 17, .	1.6	12
2	Practical Synthesis and Application of Halogen-Doped Pyrrole Building Blocks. ACS Omega, 2021, 6, 9723-9730.	1.6	7
3	New dual ATP-competitive inhibitors of bacterial DNA gyrase and topoisomerase IV active against ESKAPE pathogens. European Journal of Medicinal Chemistry, 2021, 213, 113200.	2.6	15
4	Exploring protein hotspots by optimized fragment pharmacophores. Nature Communications, 2021, 12, 3201.	5.8	28
5	Targeted Cancer Therapy Using Compounds Activated by Light. Cancers, 2021, 13, 3237.	1.7	28
6	Selective DNA Gyrase Inhibitors: Multi-Target in Silico Profiling with 3D-Pharmacophores. Pharmaceuticals, 2021, 14, 789.	1.7	5
7	Hybrid Inhibitors of DNA Gyrase A and B: Design, Synthesis and Evaluation. Pharmaceutics, 2021, 13, 6.	2.0	9
8	Dual Inhibitors of Human DNA Topoisomerase II and Other Cancer-Related Targets. Journal of Medicinal Chemistry, 2020, 63, 884-904.	2.9	126
9	Dual Escherichia coli DNA Gyrase A and B Inhibitors with Antibacterial Activity. ChemMedChem, 2020, 15, 265-269.	1.6	16
10	Design, synthesis and biological evaluation of novel DNA gyrase inhibitors and their siderophore mimic conjugates. Bioorganic Chemistry, 2020, 95, 103550.	2.0	13
11	Rational design of balanced dual-targeting antibiotics with limited resistance. PLoS Biology, 2020, 18, e3000819.	2.6	20
12	Exploring the Chemical Space of Benzothiazole-Based DNA Gyrase B Inhibitors. ACS Medicinal Chemistry Letters, 2020, 11, 2433-2440.	1.3	18
13	On the Stability and Degradation Pathways of Venetoclax under Stress Conditions. Pharmaceutics, 2020, 12, 639.	2.0	7
14	Discovery of new ATP-competitive inhibitors of human DNA topoisomerase IIÎ± through screening of bacterial topoisomerase inhibitors. Bioorganic Chemistry, 2020, 102, 104049.	2.0	6
15	Synthesis and evaluation of anticancer activity of new 9-acridinyl amino acid derivatives. RSC Medicinal Chemistry, 2020, 11, 378-386.	1.7	12
16	Second-generation 4,5,6,7-tetrahydrobenzo[d]thiazoles as novel DNA gyrase inhibitors. Future Medicinal Chemistry, 2020, 12, 277-297.	1.1	9
17	A New Cellâ€Based Alâ€2â€Mediated Quorum Sensing Interference Assay in Screening of LsrKâ€Targeted Inhibitors. ChemBioChem, 2020, 21, 1918-1922.	1.3	6
18	Efficient Synthesis of Hydroxy-Substituted 2-Aminobenzo[d]thiazole-6-carboxylic Acid Derivatives as New Building Blocks in Drug Discovery. ACS Omega, 2020, 5, 8305-8311.	1.6	12

#	Article	IF	Citations
19	ATP-competitive DNA gyrase and topoisomerase IV inhibitors as antibacterial agents. Expert Opinion on Therapeutic Patents, 2019, 29, 171-180.	2.4	41
20	New N-phenyl-4,5-dibromopyrrolamides as DNA gyrase B inhibitors. MedChemComm, 2019, 10, 1007-1017.	3.5	13
21	An optimised series of substituted N-phenylpyrrolamides as DNA gyrase B inhibitors. European Journal of Medicinal Chemistry, 2019, 167, 269-290.	2.6	36
22	Discovery of isatin and 1H-indazol-3-ol derivatives as d-amino acid oxidase (DAAO) inhibitors. Bioorganic and Medicinal Chemistry, 2018, 26, 1579-1587.	1.4	10
23	Discovery of d-amino acid oxidase inhibitors based on virtual screening against the lid-open enzyme conformation. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 1693-1698.	1.0	4
24	Influence of different classes of crosslinkers on alginate polyelectrolyte nanoparticle formation, thermodynamics and characteristics. Carbohydrate Polymers, 2018, 181, 93-102.	5.1	42
25	Design, synthesis, and biological evaluation of 1â€ethylâ€3â€(thiazolâ€2â€yl)urea derivatives as Escherichia coli DNA gyrase inhibitors. Archiv Der Pharmazie, 2018, 351, 1700333.	2.1	15
26	Heterocyclic electrophiles as new MurA inhibitors. Archiv Der Pharmazie, 2018, 351, e1800184.	2.1	22
27	A road map for prioritizing warheads for cysteine targeting covalent inhibitors. European Journal of Medicinal Chemistry, 2018, 160, 94-107.	2.6	80
28	Synthesis and Evaluation of Spumigin Analogues Library with Thrombin Inhibitory Activity. Marine Drugs, 2018, 16, 413.	2.2	4
29	Recent progress in the discovery and development of DNA gyrase B inhibitors. Future Medicinal Chemistry, 2018, 10, 1207-1227.	1.1	41
30	New N -phenylpyrrolamide DNA gyrase B inhibitors: Optimization of efficacy and antibacterial activity. European Journal of Medicinal Chemistry, 2018, 154, 117-132.	2.6	35
31	Synthesis and Evaluation of Nâ€Phenylpyrrolamides as DNA Gyraseâ€…B Inhibitors. ChemMedChem, 2018, 13, 186-198.	1.6	40
32	Discovery of substituted oxadiazoles as a novel scaffold for DNA gyrase inhibitors. European Journal of Medicinal Chemistry, 2017, 130, 171-184.	2.6	43
33	Design, Synthesis, and Evaluation of Novel Tyrosineâ€Based DNA Gyrase B Inhibitors. Archiv Der Pharmazie, 2017, 350, 1700087.	2.1	8
34	Clathrodin, hymenidin and oroidin, and their synthetic analogues as inhibitors of the voltage-gated potassium channels. European Journal of Medicinal Chemistry, 2017, 139, 232-241.	2.6	12
35	Design, synthesis and biological evaluation of 4,5-dibromo-N-(thiazol-2-yl)-1H-pyrrole-2-carboxamide derivatives as novel DNA gyrase inhibitors. Bioorganic and Medicinal Chemistry, 2017, 25, 338-349.	1.4	37
36	Linker-switch approach towards new ATP binding site inhibitors of DNA gyrase B. European Journal of Medicinal Chemistry, 2017, 125, 500-514.	2.6	9

#	Article	IF	Citations
37	Structure-activity relationships and molecular docking studies of chromene and chromene based azo chromophores: A novel series of potent antimicrobial and anticancer agents. EXCLI Journal, 2017, 16, 868-902.	0.5	29
38	3,1-Benzothiazines, 1,4-Benzodioxines and 1,4-Benzoxazines as Inhibitors of Matriptase-2: Outcome of a Focused Screening Approach. Pharmaceuticals, 2016, 9, 2.	1.7	8
39	New N -phenyl-4,5-dibromopyrrolamides and N -Phenylindolamides as ATPase inhibitors of DNA gyrase. European Journal of Medicinal Chemistry, 2016, 117, 197-211.	2.6	29
40	Discovery of Benzothiazole Scaffold-Based DNA Gyrase B Inhibitors. Journal of Medicinal Chemistry, 2016, 59, 8941-8954.	2.9	99
41	Chemistry of 2â€Aminoimidazoles. Journal of Heterocyclic Chemistry, 2016, 53, 345-355.	1.4	10
42	Discovery of 4,5,6,7-Tetrahydrobenzo[1,2-d]thiazoles as Novel DNA Gyrase Inhibitors Targeting the ATP-Binding Site. Journal of Medicinal Chemistry, 2015, 58, 5501-5521.	2.9	92
43	N-Phenyl-4,5-dibromopyrrolamides and N-Phenylindolamides as ATP Competitive DNA Gyrase B Inhibitors: Design, Synthesis, and Evaluation. Journal of Medicinal Chemistry, 2015, 58, 6179-6194.	2.9	49
44	Triterpenoid profile and bioactivity study of Oenothera maritima. Phytochemistry Letters, 2015, 13, 324-329.	0.6	5
45	Analogues of the marine alkaloids oroidin, clathrodin, and hymenidin induce apoptosis in human HepG2 and THP-1 cancer cells. MedChemComm, 2015, 6, 105-110.	3.5	12
46	Antimicrobial Activity of the Marine Alkaloids, Clathrodin and Oroidin, and Their Synthetic Analogues. Marine Drugs, 2014, 12, 940-963.	2.2	48
47	Action of Clathrodin and Analogues on Voltage-Gated Sodium Channels. Marine Drugs, 2014, 12, 2132-2143.	2.2	9
48	Substituted 4-phenyl-2-aminoimidazoles and 4-phenyl-4,5-dihydro-2-aminoimidazoles as voltage-gated sodium channel modulators. European Journal of Medicinal Chemistry, 2014, 74, 23-30.	2.6	13
49	Transformation of a selective factor Xa inhibitor rivaroxaban into a dual factor Xa/thrombin inhibitor by modification of the morpholin-3-one moiety. MedChemComm, 2014, 5, 197.	3.5	8
50	Relationship between genome and epigenome - challenges and requirements for future research. BMC Genomics, 2014, 15, 487.	1.2	24
51	A convenient strategy for synthesizing the Agelas alkaloids clathrodin, oroidin, and hymenidin and their (un)saturated linker analogs. Tetrahedron Letters, 2014, 55, 3999-4001.	0.7	11
52	Inhibition of biofilm formation by conformationally constrained indole-based analogues of the marine alkaloid oroidin. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 2530-2534.	1.0	28
53	Towards dual antithrombotic compounds â€“ Balancing thrombin inhibitory and fibrinogen GPIIb/IIIa binding inhibitory activities of 2,3-dihydro-1,4-benzodioxine derivatives through regio- and stereoisomerism. European Journal of Medicinal Chemistry, 2013, 62, 329-340.	2.6	16
54	Low molecular weight dual inhibitors of factor Xa and fibrinogen binding to GPIIb/IIIa with highly overlapped pharmacophores. European Journal of Medicinal Chemistry, 2013, 64, 302-313.	2.6	24

#	Article	IF	Citations
55	Synthesis of alkyl N-(4-nitrophenyl)-3/2-oxomorpholine-2/3-carboxylates by rhodium(II) acetate catalyzed Oâ€“H and Nâ€“H carbene insertion. Tetrahedron Letters, 2013, 54, 3341-3343.	0.7	8
56	Studies towards the Synthesis of Alkyl Nâ€(4â€Nitrophenyl)â€3/2â€oxomorpholineâ€2/3â€carboxylates. Helvetica Chimica Acta, 2013, 96, 2160-2172.	1.0	4
57	2-Aminoimidazoles in Medicinal Chemistry. Mini-Reviews in Medicinal Chemistry, 2013, 13, 1921-1943.	1.1	27
58	Advances in the Synthesis of Morpholin-3-ones and Morpholin-2-ones. Synthesis, 2012, 44, 3551-3578.	1.2	19
59	Novel 1,4-benzoxazine and 1,4-benzodioxine inhibitors of angiogenesis. European Journal of Medicinal Chemistry, 2012, 58, 160-170.	2.6	12
60	Fluorinated dual antithrombotic compounds based on 1,4-benzoxazine scaffold. European Journal of Medicinal Chemistry, 2012, 50, 255-263.	2.6	11
61	Thrombin inhibitors with lipid peroxidation and lipoxygenase inhibitory activities. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 4705-4709.	1.0	10
62	Multitarget Antithrombotic Drugs. Current Topics in Medicinal Chemistry, 2011, 11, 2834-2848.	1.0	10
63	Synthesis and antiproliferative activity of 2-(([1,2,4]triazolo[4,3-b]-) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 427 Td (pyridazin-6-y 2011, 309-322.	0.3	3
64	Peptides and pseudopeptides incorporating <scp>D</scp>â€Pheâ€“Proâ€“Arg and Argâ€“Glyâ€“Asp lead sequences as potential antithrombotic agents. Journal of Peptide Science, 2008, 14, 946-953.	0.8	6
65	Ring Opening of 2â€(Benzylamino)â€2Hâ€1,4â€benzoxazinâ€3(4H)â€ones and 2â€Bromoâ€2Hâ€1,4â€benzoxazinâ€3(4H)â€ones. Helvetica Chimica Acta, 2008, 91, 654-664.	1.0	3
66	A pentacyclic condensation product from 2,4-dimethyl-7-nitro-3-oxo-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid. Tetrahedron Letters, 2008, 49, 222-225.	0.7	4
67	3,4-Dihydro-2H-1,4-benzoxazine Derivatives Combining Thrombin Inhibitory and Glycoprotein IIb/IIIa Receptor Antagonistic Activity as a Novel Class of Antithrombotic Compounds with Dual Function. Journal of Medicinal Chemistry, 2008, 51, 5617-5629.	2.9	59
68	Novel Potent and Selective Thrombin Inhibitors Based on a Central 1,4-Benzoxazin-3(4H)-one Scaffold. Journal of Medicinal Chemistry, 2008, 51, 2863-2867.	2.9	23
69	1,4-Diazepine-2,5-dione ring formation during solid phase synthesis of peptides containing aspartic acid Î²-benzyl ester. Journal of Peptide Science, 2007, 13, 742-748.	0.8	10
70	The synthesis of alternative diketopiperazines as potential RGD mimetics. Journal of Peptide Science, 2006, 12, 663-669.	0.8	4
71	Recent advances in the synthesis of 2H-1,4-benzoxazin-3-(4H)-ones and 3,4-dihydro-2H-1,4-benzoxazines. Tetrahedron, 2005, 61, 7325-7348.	1.0	154
72	Recent Advances in the Synthesis of 2H-1,4-Benzoxazin-3-(4H)-ones and 3,4-Dihydro-2H-1,4-benzoxazines. ChemInform, 2005, 36, no.	0.1	1

#	Article	IF	Citations
73	Toward a Novel Class of Antithrombotic Compounds with Dual Function. Discovery of 1,4-Benzoxazin-3(4H)-one Derivatives Possessing Thrombin Inhibitory and Fibrinogen Receptor Antagonistic ActivitiesÂ§. Journal of Medicinal Chemistry, 2005, 48, 3110-3113.	2.9	53
74	Development of Spin-Labeled Probes for Adenosine Receptorsâ€. Journal of Medicinal Chemistry, 2005, 48, 2108-2114.	2.9	21
75	Novel Thrombin Inhibitors Incorporating Weakly Basic Heterobicyclic P1-Arginine Mimetics: Optimization via Modification of P1 and P3 Moieties.. ChemInform, 2004, 35, no.	0.1	0
76	Novel thrombin inhibitors incorporating weakly basic heterobicyclic P1-arginine mimetics: optimization via modification of P1 and P3 moieties. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 3251-3256.	1.0	8